Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.65 |
| ▸ | PPARG | P37231 | 4/20 | 0.65 |
| ▸ | FABP2 | P12104 | 2/20 | 0.65 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.65 |
| ▸ | ELANE | P08246 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496791 | 0.88 | PPARA (0.53) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL4540353 | 0.86 | PPARA (0.60) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL4540357 | 0.86 | PPARA (0.60) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL13198222 | 0.84 | TRPV1 (0.46) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL10190646 | 0.83 | PPARA (0.73) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL30657556 | 0.80 | PPARA (0.69) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL21886332 | 0.80 | CA1 (0.52) | PPARAPPARGFABP2SLC22A12SMN1; SMN2 | |
| SCHEMBL822492 | 0.79 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL13984052 | 0.79 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12ELANE | |
| Fenofibric Acid SCHEMBL16377 | 0.79 | PPARA (1.00) | PPARAPPARGFABP2SLC22A12ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189287-A1 | PERIPHERALLY RESTRICTED CB1 RECEPTOR BLOCKERS AND USES THEREOF | BIONANOSIM (BNS) LTD (IL) | 2024-06-13 | — | — | US | disclosed |
| CN-107021943-B | 7-epi-baccatin III derivatives, and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-12-29 | — | — | CN | disclosed |
| WO-2020146876-A2 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-07-16 | — | — | WO | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-02-17 | — | — | US | disclosed |
| US-6768008-B2 | FOR THERAPY | ARYX THERAPEUTICS | 2004-07-27 | — | — | US | disclosed |
| EP-1430039-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | Aryx Therapeutics (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6680387-B2 | USING THIAZOLIDINONE COMPOUND | ARYX THERAPEUTICS | 2004-01-20 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARA 305/4885PPARG 370/4885FABP2 258/4885 |
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | PPARA 1494/4885PPARG 1203/4885FABP2 4580/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARA 305/4885PPARG 370/4885FABP2 258/4885 |
| US-20240189287-A1 | PERIPHERALLY RESTRICTED CB1 RECEPTOR BLOCKERS AND USES THEREOF | CNR1, CNR2, GPR18 | PPARA 241/4885PPARG 209/4885FABP2 294/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARA 305/4885PPARG 370/4885FABP2 258/4885 |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PPARA 305/4885PPARG 370/4885FABP2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.